Galderma Labs Lp Drug Patent Portfolio
Galderma Labs Lp owns 12 orange book drugs protected by 89 US patents with Metvixia having the least patent protection, holding only 1 patent. And Soolantra with maximum patent protection, holding 14 patents. Given below is the list of Galderma Labs Lp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11628155 | Method for therapeutic treatment of rosacea | 27 Dec, 2040 | Active |
| US11426378 | Method for long-term treatment of rosacea | 18 Aug, 2040 | Active |
| US10933046 | Method for treatment of rosacea in patients aged 65 years and older | 19 Feb, 2040 | Active |
| US10945987 | Method for providing early onset of action in the treatment of rosacea | 19 Feb, 2040 | Active |
| US11541026 | Method for treatment of rosacea | 19 Feb, 2040 | Active |
| US11865100 | Method for treatment of rosacea in patients aged 65 years and older | 19 Feb, 2040 | Active |
| US11877997 | Method for providing early onset of action in the treatment of rosacea | 19 Feb, 2040 | Active |
| US11986456 | Method for treatment of rosacea | 19 Feb, 2040 | Active |
| US10420743 | Methods and compositions for the treatment of acne | 12 Jul, 2038 | Active |
| US10206939 | Treatment of papulopustular rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9089587 | Treatment of papulopustular rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9233117 | Treatment of inflammatory lesions of rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9233118 | Treatment of papulopustular rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9782425 | Treatment of papulopustular rosacea with ivermectin | 13 Mar, 2034 | Active |
| US9084778 | Topical compositions containing a retinoid of the oil-in-water emulsion type | 30 May, 2033 | Active |
| US9498465 | Topical compositions in the form of a gel containing a particular solubilized retinoid | 30 May, 2033 | Active |
| US9687465 | Compositions for the treatment of rosacea | 27 Nov, 2032 | Active |
| US12053546 | Stabilized topical formulations containing core-shell microcapsules | 29 Jun, 2032 | Active |
| US7807708 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | 19 Jul, 2031 | Active |
| US10201517 | Brimonidine gel compositions and methods of use | 13 Jun, 2031 | Active |
| US8053427 | Brimonidine gel composition | 13 Jun, 2031 | Active |
| US8163725 | Gel compositions and methods of use | 13 Jun, 2031 | Active |
| US8513247 | Methods and compositions for safe and effective treatment of erythema | 25 Mar, 2031 | Active |
| US8513249 | Methods and compositions for safe and effective treatment of erythema | 25 Mar, 2031 | Active |
| US9861631 | Methods and compositions for safe and effective treatment of erythema | 25 Mar, 2031 | Active |
| US9861632 | Methods and compositions for safe and effective treatment of erythema | 25 Mar, 2031 | Active |
| US10653899 | Core stabilized microcapsules, method of their preparation and uses thereof | 30 Dec, 2030 | Active |
| US11071878 | Core stabilized microcapsules, method of their preparation and uses thereof | 30 Dec, 2030 | Active |
| US12070629 | Core stabilized microcapsules, method of their preparation and uses thereof | 30 Dec, 2030 | Active |
| US9868103 | Metal oxide coating of water insoluble ingredients | 08 Aug, 2028 | Active |
| US7998467 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers | 31 May, 2028 | Active |
| US8617580 | Compositions for topical application comprising a peroxide and retinoid | 03 Feb, 2028 | Active |
| US7749532 | Once daily formulations of tetracyclines | 19 Dec, 2027 | Active |
| US8071644 | Combinations of adapalene and benzoyl peroxide for treating acne lesions | 18 Jul, 2027 | Active |
| US8080537 | Combinations of adapalene and benzoyl peroxide for treating acne lesions | 18 Jul, 2027 | Active |
| US8129362 | Combination/association of adapalene and benzoyl peroxide for treating acne lesions | 18 Jul, 2027 | Active |
| US8445543 | Combinations of adapalene and benzoyl peroxide for treating acne lesions | 12 Jul, 2027 | Active |
| US8435502 | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers | 15 Sep, 2026 | Active |
| US8709392 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers | 15 Sep, 2026 | Active |
| US7915243 | Topical skin care composition | 22 Mar, 2026 | Active |
| US8206740 | Once daily formulations of tetracyclines | 24 Dec, 2025 | Active |
| US8227507 | Ligands that modulate RAR receptors | 21 Dec, 2025 | Active |
| US8470871 | Ligands that modulate RAR receptors | 21 Dec, 2025 | Active |
| US7820186 | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt | 23 Nov, 2025 | Active |
| US7439241 | Compounds, formulations, and methods for treating or preventing rosacea | 25 Aug, 2025 | Active |
| US8231885 | Compounds, formulations, and methods for ameliorating telangiectasis | 24 May, 2025 | Active |
| US8410102 | Methods and compositions for treating or preventing erythema | 24 May, 2025 | Active |
| US8426410 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | 24 May, 2025 | Active |
| US7939516 | Topical skin care composition | 04 May, 2025 | Active |
| US7579377 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 23 Feb, 2025 | Active |
| US7964202 | Method for treatment of common acne | 01 Sep, 2024 | Expired |
| US7737181 | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 29 Aug, 2024 | Expired |
| US8859551 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | 25 May, 2024 | Expired |
| US11033565 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US7550440 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8080530 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8093219 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8415311 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8470788 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8815816 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | 22 Apr, 2024 | Expired |
| US8394405 | Once daily formulations of tetracyclines | 07 Apr, 2024 | Expired |
| US8394406 | Once daily formulations of tetracyclines | 07 Apr, 2024 | Expired |
| US8470364 | Once daily formulations of tetracyclines | 07 Apr, 2024 | Expired |
| US8709478 | Once daily formulations of tetracyclines | 07 Apr, 2024 | Expired |
| US7834060 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US7838558 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US7868044 | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid | 12 Mar, 2023 | Expired |
| US8703820 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders | 12 Mar, 2023 | Expired |
| US8105618 | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide | 23 Dec, 2022 | Expired |
| US8241649 | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide | 23 Dec, 2022 | Expired |
| US8809305 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris | 23 Dec, 2022 | Expired |
| US8936800 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt | 23 Dec, 2022 | Expired |
| US8653053 | Topical skin care composition | 25 Oct, 2022 | Expired |
| US8247395 | Topical skin care composition | 22 Oct, 2022 | Expired |
| US10058564 | Methods of treating acne | 05 Apr, 2022 | Expired |
| US7211267 | Methods of treating acne | 05 Apr, 2022 | Expired |
| US7232572 | Methods of treating rosacea | 05 Apr, 2022 | Expired |
| US8603506 | Methods of treating acne | 05 Apr, 2022 | Expired |
| US9241946 | Methods of treating acne | 05 Apr, 2022 | Expired |
| US6881726 | Aqueous compositions containing metronidazole | 21 Feb, 2022 | Expired |
| US7348317 | Aqueous compositions containing metronidazole | 21 Feb, 2022 | Expired |
| US6133310 | Method of treatment of rosacea | 26 Apr, 2019 | Expired |
| US5952372 | Method for treating rosacea using oral or topical ivermectin | 18 Sep, 2018 | Expired |
| US5990100 | Composition and method for treatment of psoriasis | 24 Mar, 2018 | Expired |
| US5972920 | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders | 12 Feb, 2018 | Expired |
| US6106848 | Topically applicable O/W emulsions having high glycol content and at least one biologically active agent | 22 Sep, 2017 | Expired |
| US5789395 | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production | 30 Aug, 2016 | Expired |
| US5919775 | Method for inhibiting expression of inducible nitric oxide synthase with tetracycline | 30 Aug, 2016 | Expired |
| US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy | 08 Mar, 2016 | Expired |
Latest Legal Activities on Galderma Labs Lp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Galderma Labs Lp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 15 May, 2024 | US9498465 |
|
Maintenance Fee Reminder Mailed
Critical
| 08 Apr, 2024 | US8247395 |
|
Maintenance Fee Reminder Mailed
Critical
| 01 Apr, 2024 | US8241649 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11541026 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Mar, 2024 | US11628155 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11426378 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Mar, 2024 | US11426378 |
|
Email Notification
Critical
| 21 Mar, 2024 | US11628155 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 21 Mar, 2024 | US11541026 |
|
Expire Patent
Critical
| 04 Mar, 2024 | US8105618 |
| Mail Patent eCofC Notification | 20 Feb, 2024 | US11865100 |
|
Email Notification
Critical
| 20 Feb, 2024 | US11865100 |
| Patent eCofC Notification | 20 Feb, 2024 | US11865100 |
| Recordation of Patent eCertificate of Correction | 20 Feb, 2024 | US11865100 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 13 Feb, 2024 | US10945987 |
Galderma Labs Lp's Drug Patent Litigations
Galderma Labs Lp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 16, 2014, against patent number US8426410. The petitioner , challenged the validity of this patent, with Jack Dejovin et al as the respondent. Click below to track the latest information on how companies are challenging Galderma Labs Lp's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8603506 | August, 2015 |
Terminated-Denied
(16 Feb, 2016)
| GALDERMA LABORATORIES, INC. | Dr. Reddy’s Laboratories, Ltd. |
| US8206740 | June, 2013 |
FWD Entered
(09 Dec, 2014)
| ||
| US8394405 | June, 2013 |
FWD Entered
(09 Dec, 2014)
| Supernus Pharmaceuticals, Inc. | Amneal Pharamceuticals, LLC |
| US8394406 | June, 2013 |
FWD Entered
(09 Dec, 2014)
| ||
| US7439241 | May, 2014 |
Decision
(16 May, 2014)
| Jack Dejovin et al | |
| US8426410 | May, 2014 |
Decision
(16 May, 2014)
| Jack Dejovin et al | |
Galderma Labs Lp Drug Patents' Oppositions Filed in EPO
Galderma Labs Lp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 26, 2012, by Allergan, Inc.. This opposition was filed on patent number EP04753601A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP13726504A | Apr, 2019 | Generics (U.K.) Limited | Patent maintained as amended |
| EP13728696A | Mar, 2019 | Generics (UK) Ltd | Patent maintained as amended |
| EP08708470A | Mar, 2016 | Generics (U.K.) Limited | Revoked |
| EP11185810A | Apr, 2015 | Beiersdorf AG | Patent maintained as amended |
| EP07787478A | Mar, 2014 | Generics [UK] Limited | Opposition rejected |
| EP04753601A | Jul, 2012 | ALLERGAN, INC. | Patent maintained as amended |
Galderma Labs Lp's Family Patents
Galderma Labs Lp drugs have patent protection in a total of 38 countries. It's US patent count contributes only to 31.6% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Galderma Labs Lp Drug List
Given below is the complete list of Galderma Labs Lp's drugs and the patents protecting them.
1. Aklief
Aklief is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9084778 | Topical compositions containing a retinoid of the oil-in-water emulsion type |
30 May, 2033
(8 years from now)
| Active |
| US9498465 | Topical compositions in the form of a gel containing a particular solubilized retinoid |
30 May, 2033
(8 years from now)
| Active |
| US7807708 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
19 Jul, 2031
(6 years from now)
| Active |
| US8227507 | Ligands that modulate RAR receptors |
21 Dec, 2025
(1 year, 2 days from now)
| Active |
| US8470871 | Ligands that modulate RAR receptors |
21 Dec, 2025
(1 year, 2 days from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Aklief's drug page
2. Clobex
Clobex is protected by 3 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5990100 | Composition and method for treatment of psoriasis |
24 Mar, 2018
(6 years ago)
| Expired |
| US5972920 | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
12 Feb, 2018
(6 years ago)
| Expired |
| US6106848 | Topically applicable O/W emulsions having high glycol content and at least one biologically active agent |
22 Sep, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Clobex's drug page
3. Differin
Differin is protected by 9 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7998467 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
31 May, 2028
(3 years from now)
| Active |
| US8435502 | Cosmetic/dermatological compositions comprising naphtholic acid compounds and polyurethane polymers |
15 Sep, 2026
(1 year, 8 months from now)
| Active |
| US8709392 | Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers |
15 Sep, 2026
(1 year, 8 months from now)
| Active |
| US7579377 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
23 Feb, 2025
(2 months from now)
| Active |
| US7737181 | Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
29 Aug, 2024
(3 months ago)
| Expired |
| US7834060 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US7838558 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US7868044 | Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
12 Mar, 2023
(1 year, 9 months ago)
| Expired |
| US8703820 | Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders |
12 Mar, 2023
(1 year, 9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Differin's drug page
4. Epiduo
Epiduo is protected by 10 patents, out of which 5 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8071644 | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
18 Jul, 2027
(2 years from now)
| Active |
| US8080537 | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
18 Jul, 2027
(2 years from now)
| Active |
| US8129362 | Combination/association of adapalene and benzoyl peroxide for treating acne lesions |
18 Jul, 2027
(2 years from now)
| Active |
| US8445543 | Combinations of adapalene and benzoyl peroxide for treating acne lesions |
12 Jul, 2027
(2 years from now)
| Active |
| US7820186 | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
23 Nov, 2025
(11 months from now)
| Active |
| US7964202 | Method for treatment of common acne |
01 Sep, 2024
(3 months ago)
| Expired |
| US8105618 | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
23 Dec, 2022
(1 year, 11 months ago)
| Expired |
| US8241649 | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide |
23 Dec, 2022
(1 year, 11 months ago)
| Expired |
| US8809305 | Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris |
23 Dec, 2022
(1 year, 11 months ago)
| Expired |
| US8936800 | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
23 Dec, 2022
(1 year, 11 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epiduo's drug page
5. Epsolay
Epsolay is protected by 10 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11628155 | Method for therapeutic treatment of rosacea |
27 Dec, 2040
(16 years from now)
| Active |
| US11426378 | Method for long-term treatment of rosacea |
18 Aug, 2040
(15 years from now)
| Active |
| US10933046 | Method for treatment of rosacea in patients aged 65 years and older |
19 Feb, 2040
(15 years from now)
| Active |
| US10945987 | Method for providing early onset of action in the treatment of rosacea |
19 Feb, 2040
(15 years from now)
| Active |
| US11541026 | Method for treatment of rosacea |
19 Feb, 2040
(15 years from now)
| Active |
| US11865100 | Method for treatment of rosacea in patients aged 65 years and older |
19 Feb, 2040
(15 years from now)
| Active |
| US11877997 | Method for providing early onset of action in the treatment of rosacea |
19 Feb, 2040
(15 years from now)
| Active |
| US11986456 | Method for treatment of rosacea |
19 Feb, 2040
(15 years from now)
| Active |
| US9687465 | Compositions for the treatment of rosacea |
27 Nov, 2032
(7 years from now)
| Active |
| US9868103 | Metal oxide coating of water insoluble ingredients |
08 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Epsolay's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Metrogel
Metrogel is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6881726 | Aqueous compositions containing metronidazole |
21 Feb, 2022
(2 years ago)
| Expired |
| US7348317 | Aqueous compositions containing metronidazole |
21 Feb, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metrogel's drug page
7. Metvixia
Metvixia is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
08 Mar, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Metvixia's drug page
8. Mirvaso
Mirvaso is protected by 12 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10201517 | Brimonidine gel compositions and methods of use |
13 Jun, 2031
(6 years from now)
| Active |
| US8053427 | Brimonidine gel composition |
13 Jun, 2031
(6 years from now)
| Active |
| US8163725 | Gel compositions and methods of use |
13 Jun, 2031
(6 years from now)
| Active |
| US8513247 | Methods and compositions for safe and effective treatment of erythema |
25 Mar, 2031
(6 years from now)
| Active |
| US8513249 | Methods and compositions for safe and effective treatment of erythema |
25 Mar, 2031
(6 years from now)
| Active |
| US9861631 | Methods and compositions for safe and effective treatment of erythema |
25 Mar, 2031
(6 years from now)
| Active |
| US9861632 | Methods and compositions for safe and effective treatment of erythema |
25 Mar, 2031
(6 years from now)
| Active |
| US7439241 | Compounds, formulations, and methods for treating or preventing rosacea |
25 Aug, 2025
(8 months from now)
| Active |
| US8231885 | Compounds, formulations, and methods for ameliorating telangiectasis |
24 May, 2025
(5 months from now)
| Active |
| US8410102 | Methods and compositions for treating or preventing erythema |
24 May, 2025
(5 months from now)
| Active |
| US8426410 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
24 May, 2025
(5 months from now)
| Active |
| US8859551 | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders |
25 May, 2024
(6 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mirvaso's drug page
9. Oracea
Oracea is protected by 13 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7749532 | Once daily formulations of tetracyclines |
19 Dec, 2027
(3 years from now)
| Active |
| US8206740 | Once daily formulations of tetracyclines |
24 Dec, 2025
(1 year, 5 days from now)
| Active |
| US8394405 | Once daily formulations of tetracyclines |
07 Apr, 2024
(8 months ago)
| Expired |
| US8394406 | Once daily formulations of tetracyclines |
07 Apr, 2024
(8 months ago)
| Expired |
| US8470364 | Once daily formulations of tetracyclines |
07 Apr, 2024
(8 months ago)
| Expired |
| US8709478 | Once daily formulations of tetracyclines |
07 Apr, 2024
(8 months ago)
| Expired |
| US10058564 | Methods of treating acne |
05 Apr, 2022
(2 years ago)
| Expired |
| US7211267 | Methods of treating acne |
05 Apr, 2022
(2 years ago)
| Expired |
| US7232572 | Methods of treating rosacea |
05 Apr, 2022
(2 years ago)
| Expired |
| US8603506 | Methods of treating acne |
05 Apr, 2022
(2 years ago)
| Expired |
| US9241946 | Methods of treating acne |
05 Apr, 2022
(2 years ago)
| Expired |
| US5789395 | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
30 Aug, 2016
(8 years ago)
| Expired |
| US5919775 | Method for inhibiting expression of inducible nitric oxide synthase with tetracycline |
30 Aug, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Oracea's drug page
10. Soolantra
Soolantra is protected by 14 patents, out of which 9 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10206939 | Treatment of papulopustular rosacea with ivermectin |
13 Mar, 2034
(9 years from now)
| Active |
| US9089587 | Treatment of papulopustular rosacea with ivermectin |
13 Mar, 2034
(9 years from now)
| Active |
| US9233117 | Treatment of inflammatory lesions of rosacea with ivermectin |
13 Mar, 2034
(9 years from now)
| Active |
| US9233118 | Treatment of papulopustular rosacea with ivermectin |
13 Mar, 2034
(9 years from now)
| Active |
| US9782425 | Treatment of papulopustular rosacea with ivermectin |
13 Mar, 2034
(9 years from now)
| Active |
| US11033565 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(7 months ago)
| Expired |
| US7550440 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(7 months ago)
| Expired |
| US8080530 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(7 months ago)
| Expired |
| US8093219 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(7 months ago)
| Expired |
| US8415311 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(7 months ago)
| Expired |
| US8470788 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(7 months ago)
| Expired |
| US8815816 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
22 Apr, 2024
(7 months ago)
| Expired |
| US6133310 | Method of treatment of rosacea |
26 Apr, 2019
(5 years ago)
| Expired |
| US5952372 | Method for treating rosacea using oral or topical ivermectin |
18 Sep, 2018
(6 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Soolantra's drug page
11. Tri-luma
Tri-luma is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7915243 | Topical skin care composition |
22 Mar, 2026
(1 year, 3 months from now)
| Active |
| US7939516 | Topical skin care composition |
04 May, 2025
(4 months from now)
| Active |
| US8653053 | Topical skin care composition |
25 Oct, 2022
(2 years ago)
| Expired |
| US8247395 | Topical skin care composition |
22 Oct, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tri-luma's drug page
12. Twyneo
Twyneo is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10420743 | Methods and compositions for the treatment of acne |
12 Jul, 2038
(13 years from now)
| Active |
| US12053546 | Stabilized topical formulations containing core-shell microcapsules |
29 Jun, 2032
(7 years from now)
| Active |
| US10653899 | Core stabilized microcapsules, method of their preparation and uses thereof |
30 Dec, 2030
(6 years from now)
| Active |
| US11071878 | Core stabilized microcapsules, method of their preparation and uses thereof |
30 Dec, 2030
(6 years from now)
| Active |
| US12070629 | Core stabilized microcapsules, method of their preparation and uses thereof |
30 Dec, 2030
(6 years from now)
| Active |
| US9868103 | Metal oxide coating of water insoluble ingredients |
08 Aug, 2028
(3 years from now)
| Active |
| US8617580 | Compositions for topical application comprising a peroxide and retinoid |
03 Feb, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Twyneo's drug page